AlphaYou
Overview
Smart money at a glance
Filings to Oct 7, 2026Net selling: insiders sold $72.3M and bought $40K on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- -$72.3M netNet selling
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 3 added, 0 cutMore adding
- Federal contractsUSAspending.gov, last 12 months
- No awardsNone on record
Market overview
Fundamentals Oct 7- Open
- $16.03
- 52-wk high
- $27.30
- High
- $16.03
- 52-wk low
- $13.72
- Low
- $15.09
- Prev close
- $15.82
- Mkt cap
- $2.88B
- Volume
- 2.50M
- Beta
- 1.12
- P/B
- 4.3x
- Profit margin
- +0.0%
- Op margin
- +0.0%
- ROE
- -81.6%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about DYN filings
Are insiders buying or selling Dyne Therapeutics Inc (DYN) stock?
Net selling: insiders sold $72.3M and bought $40K of DYN stock on the open market in the 90 days to Oct 7, 2026, according to SEC Form 4 filings. $72.3M of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Rhodes, Jason P (Director), who sold $65.2M. The latest filing was on Oct 6, 2026.
Which members of Congress have traded DYN recently?
None. No member of Congress disclosed a DYN trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this DYN smart-money data?
This summary uses filings available on Oct 7, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Buys/Adds (3)
- CI
Citadel
$21.8M
added
- MW
Marshall Wace
$31.6M
added
- BO
Bank of America
$23.4M
added
What insiders are doing
How top traders are positioned
No tracked top-trader positions in DYN right now.
Live Hyperliquid positioning - not every stock is covered
Activist stakes, short interest & more
Earnings
Earnings came in 31.1% below what analysts expected.
Last report
Jul 27, 2026
Period ending
Jun 30, 2026
Earnings per share
-$0.74 expected
Revenue
No reported revenue on record
Previous reports
All values in USD| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / estimate | Rev. surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Jul 27, 2026 | -$0.97 / -$0.74Alpha Vantage | -31.08% miss | Unavailable | Unavailable |
| Mar 31, 2026 | May 11, 2026 | -$0.73 / -$0.78Alpha Vantage | +6.41% beat | Unavailable | Unavailable |
| Dec 31, 2025 | Mar 2, 2026 | -$0.73 / -$0.77Alpha Vantage | +5.48% beat | Unavailable | Unavailable |
| Sep 30, 2025 | Nov 5, 2025 | -$0.76 / -$0.81Alpha Vantage | +6.17% beat | Unavailable | Unavailable |
| Jun 30, 2025 | Jul 28, 2025 | -$0.97 / -$0.93Alpha Vantage | -4.30% miss | Unavailable | Unavailable |
| Mar 31, 2025 | May 8, 2025 | -$1.05 / -$0.84Alpha Vantage | -25.00% miss | Unavailable | Unavailable |
| Dec 31, 2024 | Feb 27, 2025 | -$0.88 / -$0.91Alpha Vantage | +3.51% beat | Unavailable | Unavailable |
| Sep 30, 2024 | Nov 12, 2024 | -$0.96 / -$0.71Alpha Vantage | -35.21% miss | Unavailable | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue uses company releases and saved estimates.
Reports Nov 4, 2026, in 28 days
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $0 | $0 | $0 | $0 |
| Cost of what it sold | — | $521.0K | $550.0K | — |
| Gross profit | — | -$521.0K | -$550.0K | — |
| What it spent | ||||
| Research and development | $97.2M | $95.4M | $100.9M | $152.2M |
| Sales and admin | $16.7M | $20.7M | $24.4M | $29.5M |
| Total operating expenses | $113.9M | $115.6M | $125.3M | $181.7M |
| What was left | ||||
| Operating profit | -$113.9M | -$116.1M | -$125.3M | -$181.7M |
| Interest on debt | $2.9M | $3.2M | $4.2M | $4.6M |
| Profit before tax | -$108.0M | -$112.0M | -$120.9M | -$178.6M |
| Net profit | -$108.0M | -$112.0M | -$120.9M | -$178.6M |
| EBITDA | -$104.6M | -$101.2M | -$116.1M | -$173.4M |
Technicals
Price structure
This stock is under pressure, and looks oversold after a sharp drop.
Trend
Under pressure
0 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage is bullish
Analysts Offer Insights on Healthcare Companies: Medios AG (OtherMEDOF) and Dyne Therapeutics (DYN)
BullishOct 1Cantor Fitzgerald reiterates Dyne Therapeutics stock rating
NeutralOct 1Dyne Therapeutics Is Maintained at Buy by Chardan Capital
BullishSep 30Dyne Therapeutics stock rises on positive DM1 trial results
BullishSep 30DYN Maintained by Chardan Capital -- Price Target Holds at $38
BullishSep 30Chardan Capital maintains Buy rating on Dyne Therapeutics, $38 price target
NeutralSep 30Is Dyne Therapeutics (DYN) A Bargain After ACHIEVE Trial Data?
NeutralSep 30Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)
BullishSep 29
Macro
23 macro signals shaping DYN right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results